Overview

A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease

Status:
Not yet recruiting
Trial end date:
2025-02-17
Target enrollment:
Participant gender:
Summary
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be efficacious over longer periods of time.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals